<DOC>
	<DOCNO>NCT00644787</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety fentanyl 1-day application ( JNS020QD ) transdermal patch ( patch contain drug put skin drug enter body skin ) ass non-inferiority fentanyl 1-day application transdermal patch fentanyl 3-day application ( JNS005 ) transdermal patch participant cancer pain .</brief_summary>
	<brief_title>A Dose-Finding Study Fentanyl ( JNS020 QD ) 1-Day Transdermal Patch Participants With Cancer Pain</brief_title>
	<detailed_description>This multi-center ( conducted one center ) study , consist two period : Period 1 open-label ( people know identity intervention ) , non-comparative dose titration phase Period 2 double blind ( neither physician participant know treatment participant receives ) , positive control ( fentanyl 3-day application transdermal patch use control drug ) phase . In Period 1 , fentanyl 1-day application transdermal patch 12.5 microgram per hour ( mcg/hr ) apply chest , abdomen , upper arm thigh maintain 2 day ensure safety participant . Dose escalation reduction allow base participant 's condition Day 3 Day 11 thereafter dose maintain Day 11 Day 13 maximum application dose 100 mcg/hr . The total duration Period 1 14 day ( total 13 application ; include day final patch removal ) . Participants meet predefined criterion end dose titration phase enter double blind phase . In double blind phase , participant receive either fentanyl 1-day application transdermal patch placebo match fentanyl 3-day application transdermal patch fentanyl 3-day application transdermal patch placebo match fentanyl 1-day application transdermal patch dose use completion Period 1 . The duration Period 2 10 day . Efficacy primarily evaluate percentage participant achieve dose titration success change mean visual analog scale ( VAS ) score . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Participants cancer pain previously treat opioid analgesic ( drug use control pain ) Participants pain score great equal 35 millimeter ( mm ) 100mm visual analog scale ( VAS ) Participants consider `` insufficient response '' nonopioid analgesic require treatment opioid analgesic physician Participants establish diagnosis cancer notify disease Participants hospitalize Period 1 ( dosetitration period ) Participants impaired respiratory function due chronic lung disease others Participants asthma ( breathe disorder wheeze difficulty breathe ) Participants bradyarrhythmia ( slow , irregular heartbeat ) Participants follow measurement indicative hepatic renal impairment pretreatment observation period : Aspartate transaminase ( AST ) great 5 time upper limit reference range , Alanine transaminase ( ALT ) great 5 time upper limit reference range , serum creatinine great 3 time upper limit reference range Participants cerebral damage , brain tumor , accompany increase intracranial pressure , disturbance consciousness , coma , respiratory disturbance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>JNS020QD</keyword>
	<keyword>JNS005</keyword>
</DOC>